Acceptance, panic, and partial recovery: The pattern of usage of drug-eluting stents after introduction in the U.S. (a report from the american college of cardiology/national cardiovascular data registry)

JACC: Cardiovascular Interventions

Volumn 3, Issue 9, 2010, Pages 902-910

  Krone, Ronald J ^a   Rao, Sunil V ^b   Dai, David ^b   Anderson, H Vernon ^c   Peterson, Eric D ^b   Brown, Michael A ^d   Brindis, Ralph G ^e   Klein, Lloyd W ^f   Shaw, Richard E ^g   Weintraub, William S ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KAISER PERMANENTE   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g Sutter Pacific Heart Centers   (United States)

^h CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

coronary artery stents; drug eluting stents; outcomes assessment; percutaneous coronary intervention; stent thrombosis

Indexed keywords

CLINICAL FEATURE; CORONARY STENT; DRUG ELUTING STENT; HEALTH INSURANCE; HUMAN; IN-STENT RESTENOSIS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

EID: 77955866404     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.06.014     Document Type: Article

References (30)

1. M.C. Morice, P.W. Serruys, and J.E. Sousa A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. S.V. Rao, R.E. Shaw, R.G. Brindis, L.W. Klein, W.S. Weintraub, and E.D. Peterson On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]) Am J Cardiol 97 2006 1478 1481
4. N.I. Muni, and T.P. Gross Problems with drug-eluting coronary stentsthe FDA Perspective N Engl J Med 351 2004 1593 1595
5. R. Virmani, F.D. Kolodgie, and A. Farb Drug-eluting stents: are they really safe? Am Heart Hosp J 2 2004 85 88
6. E.P. McFadden, E. Stabile, and E. Regar Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521 (Pubitemid 39410418)
7. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents J Am Coll Cardiol 48 2006 2584 2591
8. B. Lagerqvist, S.K. James, and U. Stenestrand Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
9. E. Camenzind, P.G. Steg, and W. Wijns A cause for concern Circulation 115 2007 1440 1455
10. S.P. Westphal Concerns prompt some hospitals to pare use of drug-coated stents June 22, 2006 Wall Street Journal Washington D.C
11. J.J. Popma, B. Weiner, M.J. Cowley, D. Simonton, D. McKormack, and T. Feldman FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations J Interv Card 20 2007 425 446
12. J. Daemen, S. Tanimoto, and H.M. Garca-Garca Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction Am J Card 99 2007 1027 1032
13. H.V. Anderson Drug-eluting stents: life insurance with a better death benefit J Am Coll Cardiol 51 2008 2025 2027
14. R.J. Applegate, M.T. Sacrinty, and M.A. Kutcher "Off-label" stent therapy: 2-year comparison of drug-eluting versus bare-metal stents J Am Coll Cardiol 51 2008 607 614
15. E.L. Hannan, M. Racz, and G. Walford Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction J Am Coll Cardiol Intv 1 2008 129 135
16. D.J. Malenka, A.V. Kaplan, F.L. Lucas, S.M. Sharp, and J.S. Skinner Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents JAMA 299 2008 2868 2876
17. P.S. Douglas, J.M. Brennan, and K.J. Anstrom Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the ACC/NCDR J Am Coll Cardiol 53 2009 1629 1641
18. R.G. Brindis, S. Fitzgerald, H.V. Anderson, R.E. Shaw, W.S. Weintraub, and J.F. Williams The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository J Am Coll Cardiol 37 2001 2240 2245
19. M.T. Roe, A.Y. Chen, and C.P. Cannon Temporal changes in the use of drug-eluting stents for patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from CRUSADE and ACTION-GWTG registries Circ Cardiovasc Qual Outcomes 2 2009 414 420
20. A.V. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
21. J.V. Tu, J. Bowen, and M. Chiu Effectiveness and safety of drug-eluting stents in Ontario N Engl J Med 357 2007 1393 1402
22. M.H. Shishehbor, S.S. Goel, and S.R. Kapadia Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality J Am Coll Cardiol 52 2008 1041 1048
23. P.W. Groeneveld, M.A. Matta, A.P. Greenhut, and F. Yang Drug-eluting compared with bare-metal coronary stents among elderly patients J Am Coll Cardiol 51 2008 2017 2024
24. D.-W. Park, S.-C. Yun, and S.-W. Lee Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents J Am Coll Cardiol Intv 1 2008 494 503
25. L.O. Jensen, M. Maeng, and A. Kaltoft Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions J Am Coll Cardiol 50 2007 463 470
26. J.A. Spertus, R. Kettelkamp, and C. Vance Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809
27. S.B. King III, S.C. Smith Jr., J.W. Hirshfeld Jr., A.K. Jacobs, D.A. Morrison, and D.O. Williams 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention J Am Coll Cardiol 51 2008 172 209
28. J.M. Lasala, D.A. Cox, and D. Dobies Usage patterns and 2-year outcomes with the TAXUS express stent: (ARRIVE-1 Registry) Catheter Cardiovasc Interv 72 2008 433 445
29. B.L. Strom How the US drug safety system should be changed JAMA 295 2006 2072 2075
30. P. Slottow, L. Tina, and R. Waksman Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor zotarolimus-eluting coronary stent Circulation 117 2008 1603 1608